SenzaGen AB reported consolidated sales results for the first quarter of 2023. Consolidated net sales in the January- March period increased by 36% to SEK 12.3 million driven by strong GARD® sales from new and returning major global customers combined with growth in VitroScreen's innovation services for medical devices, cosmetics and pharmaceuticals.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8 SEK | +6.38% | +25.39% | +9.89% |
Mar. 25 | Senzagen Receives Follow-Up Order Worth SEK 0.8 Million from the Global Chemicals Leader | CI |
Mar. 22 | SenzaGen AB Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+9.89% | 17.91M | |
-16.10% | 11.41B | |
+67.65% | 3.81B | |
-14.31% | 2.16B | |
-26.03% | 1.56B | |
+36.95% | 1.19B | |
-2.40% | 760M | |
-19.00% | 506M | |
-38.57% | 444M | |
+13.72% | 339M |
- Stock Market
- Equities
- SENZA Stock
- News SenzaGen AB
- SenzaGen AB Reports Consolidated Sales Results for the First Quarter of 2023